Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a 1,500-Patient biobank unlock the secrets of chronic pancreatitis?

NCT ID NCT07770412

Knowledge-focused Sponsor: First People's Hospital of Hangzhou Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time

Summary

This observational study will follow 1,500 adults with chronic pancreatitis for several years, collecting health data and biological samples like blood, stool, and bile. The goal is to track how the disease changes over time, especially in those undergoing ERCP treatment, and to identify factors linked to complications or pancreatic cancer. By building a detailed biobank, researchers hope to improve future diagnosis and care for this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
This research could lead to better ways to monitor chronic pancreatitis, predict complications, and improve treatment decisions for ERCP procedures.
What could go wrong
As an observational study, it cannot prove cause and effect. The findings may not apply to all patients, and long-term follow-up may be challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Aug 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of adult patients (aged 18 years and older, regardless of sex) who are clinically diagnosed with chronic pancreatitis and are receiving medical care at the study center (Hangzhou First People's Hospital) in Hangzhou, Zhejiang Province, China.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, with no sex restrictions. * Meets the diagnostic criteria for chronic pancreatitis, with a definitive diagnosis of chronic pancreatitis based on imaging, pathology, or pancreatic function tests; * Receiving medical care at the study center and willing to accept long-term follow-up management. * Able to cooperate with baseline data collection and scheduled follow-ups. * Provided written informed consent. Exclusion Criteria: * Concomitant malignancies. * Concurrent severe systemic diseases with an expected life expectancy of \< 1 year. * History of major pancreatic resection or pancreaticoduodenectomy. * History of major gastrointestinal surgery. * Pregnant or lactating population. * Severe psychiatric disorders, cognitive dysfunction, or assessed by the investigator as having extremely poor compliance, rendering the participant unable to complete the scheduled follow-up plan. * Other relevant conditions deemed by the investigator as potentially affecting the study results or compromising participant safety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pancreatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic pancreatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pancreatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • First People's Hospital of Hangzhou

    Hangzhou, Zhejiang, 310006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.